Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

Oncotarget

Volumn 7, Issue 11, 2016, Pages 13260-13264

  Villasboas, Jose Caetano ^a   Ansell, Stephen M ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic stem cell transplantation; Hodgkin lymphoma; Immunotherapy; PD 1 inhibitors; Pembrolizumab

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; NAVELBINE; PANOBINOSTAT; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; VINBLASTINE;

ABDOMINAL MASS; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LOW DRUG DOSE; LYMPHADENOPATHY; MALE; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; PROTEIN TARGETING; TUMOR BIOPSY;

EID: 84962897493     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7177     Document Type: Article

References (12)

1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015; 372(4):311-319.
2. Moskowitz CH, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M, De Maeyer G, Jacob AG, Giallella K, Weimer Anderson J, Derosier M, Wang J, Yang Z, Rubin E, Rose S, Shipp MA, et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood. 2014; 124(21):290-290.
3. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, Garcia-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Diez JL, Moraleda JM, Rubio-Felix D, Xicoy B, Martinez C, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12(2):172-183.
4. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcarcel D, Besalduch J, Duarte R, Leon A, Pascual MJ, Garcia-Noblejas A, Lopez Corral L, Xicoy B, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012; 97(2):310-317.
5. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V and Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010; 85(5):320-324.
6. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R and Dolstra H. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011; 71(15):5111-5122.
7. Sanmamed MF, Rodriguez I, Schalper KA, Onate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Perez-Gracia JL, Martin-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, et al. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rgammanull Immunodeficient Mice. Cancer Res. 2015; 75(17):3466-3478.
8. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ and Ball ED. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009; 113(7):1581-1588.
9. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A and Nagler A. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(10):3044-3051.
10. Cecchini M, Sznol M and Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. J Immunother Cancer. 2015; 3:10.
11. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schafers M, Groth C, Kessler T, Lenz G, Stelljes M and Berdel WE. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015. doi: 10.1038/bmt.2015.266. [Epub ahead of print].
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-956.